Abstract:TREM2 is a microglial receptor, sensitive to Phospholipids and Sphingomyelins, associated with neurodegeneration. Hypomorphic variants in the TREM2 gene significantly increase the risk of developing AD. The main aim of this study was to characterize networks of lipids in post-mortem brain from AD and control donors, and to identify key lipids that are associated with AD and impacted by dysfunctional TREM2. We studied human post-mortem brain tissue from the hippocampus and the BA9 pre-association cortex from a total of 102 post-mortem brains. Specifically, brain tissue from the BA9 pre-association cortex was available for n=55 donors and brain tissue from the hippocampus was available for n=47 brain donors from three groups: AD donors with a non-synonymous risk DNA variant in TREM2 (AD-TREM2var), AD donors with no TREM2-associated variant (AD-TREM2wt), and control donors. Mass Spectrometry was performed to obtain lipidomic signatures spanning 99 lipid species that included the following lipid classes: Ceramides, Sphingomyelins, Phosphatidic acids, Phopshatidyl-cholines, Phosphatidyl-ethalonamines, Phosphatidyl-glycerols, Phosphatidyl-inositols, Phosphatidyl-serines and Triglycerides. Weighted gene co-expression network analysis (WGCNA) was used to identify highly correlated lipid modules and hub lipids. Linear mixed models and linear regression analyses, adjusted for age, biological sex, number of APOE e4 alleles and post-mortem delay were used to assess the association of modules and individual hub lipids with AD and TREM2 status. Four lipid modules were found to be relatively well-preserved between the two brain regions, and three of these modules were altered in AD donors and/or in AD donors with TREM2 genetic variants. Levels of the BA9 turquoise module (blue hippocampus module), enriched in Sphingolipids and Phospholipids, were elevated in AD brain donors and in AD TREM2 carriers. The key lipid (hub) of the BA9 turquoise/ hippocampus blue module was a Phosphatidylserine (PS(32:1)), increased in both AD donors and TREM2 carriers (AD-TREM2wt versus controls: beta=0.468, 95% CI 0.05 - 0.89, p= 3.02E-02; and AD-TREM2var versus controls: beta=1.00, 95% CI 0.53 - 1.47, p= 5.57E-03), whereas the strongest association was observed with a Ceramide (Cer(d38:1)) (AD-TREM2wt versus controls: beta=0.663, 95% CI 0.17 - 1.16, p= 8.9E-03; and AD-TREM2var versus controls: beta=1.31, 95% CI 0.78 - 1.84, p= 4.35E-06). The consistent increase in TREM2 ligands such as Ceramides and Phosphatidyl-serines in the brains of AD donors, particularly in carriers of TREM2 risk variants, could reflect the presence of AD-associated damage signals in the form of stressed/apoptotic cells and damaged myelin.

Alterations in the Brain Lipidome of Alzheimer's Disease Donors with Rare TREM2 Risk Variants

Insights into lipid-modified recognition of Apolipoprotein E3 to extra-cellular domain of TREM2 associated with Alzheimer's disease

Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease

Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease

TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge

TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target

Integrative Metabolomics and Whole Transcriptome Sequencing Reveal Role for TREM2 in Metabolism Homeostasis in Alzheimer's Disease

A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression

Apolipoprotein E is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)*

Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease.

Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology

Understanding the binding mechanisms of Alzheimer risk factor TREM2 in lipid bilayer using multi-scale molecular dynamics simulations

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology

The flexible stalk domain of sTREM2 modulates its interactions with phospholipids in the brain

TREM2 in Alzheimer’s Disease

Defects in lysosomal function and lipid metabolism in human microglia harboring a TREM2 loss of function mutation

Alzheimer's disease‐associated R47H TREM2 increases, but wild‐type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism